Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026
Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.
How this was made

The 30-second read
Why it matters
For ABT, the key trade is balancing accelerating PFA ablation adoption and new FDA/CE milestones against a stated near-term headwind from LAA order delays.
Market read
Company-specific regulatory approvals and launch timing for EP devices are actionable for positioning into Q4, but the LAA demand slowdown adds uncertainty to near-term earnings trajectory.
What to watch
The piece does not quantify how much LAA weakness offsets EP acceleration, so traders may need to monitor order cadence and reimbursement or competitive dynamics not discussed here.
Background
The article frames Abbott’s 2026 EP performance around Volt PFA adoption and a growing EP catheter portfolio, while flagging LAA demand softness after Amulet 360 CE Mark.
Ticker impact
Abbott reports ABT Medical Devices EP sales growth and details FDA approval for its TactiFlex Duo PFA/RF catheter plus Volt launch expectations.
Likely modest upside bias as investors price in Volt/TactiFlex ramp, tempered by near-term LAA order softness.
The article provides multiple company-specific catalysts (FDA approval, Japan launch timing, U.S. full-quarter contribution) alongside a concrete demand headwind (slower U.S. LAA orders after Amulet 360 CE Mark).
Market effects
Signals continued adoption of pulsed field ablation and expanding electrophysiology device portfolios, which can influence sentiment across cardiac ablation and device peers.
Highlights Japan as a potential tailwind for Volt adoption, suggesting regional diffusion dynamics for PFA technology.
Reinforces a broader medtech theme of electrophysiology procedure growth driven by new energy modalities, with Europe and U.S. adoption patterns in focus.
Counterpoint
The LAA slowdown tied to Amulet 360 CE Mark could dominate near-term results, making EP growth less supportive than it appears.
Key entities
- companyAbbott Laboratories
ABT Medical Devices segment, with EP growth drivers (Volt PFA, TactiFlex Duo FDA approval) and LAA headwind (Amulet 360 CE Mark order delays).
- productVolt pulsed field ablation catheter
Abbott’s PFA catheter whose adoption accelerated after U.S. market release and is expected to launch in Japan in Q4.
- productTactiFlex Duo Ablation Catheter, Sensor Enabled
FDA-approved catheter allowing PFA, RF, or combination use, with broader U.S. launch expected in Q4.
- productAmulet 360 LAA Occluder
CE-marked LAA occluder; U.S. orders reportedly slowed after CE Mark approval as accounts delayed purchases.


